CEP17 Breast Cancer Tumors Are More Likely to Respond to Anthracyclines
BARCELONA—Breast cancer patients with the chromosome enumeration probe 17 (CEP17) alpha satellite abnormality are more likely to have good outcomes from chemotherapy involving anthracycline antibiotics than women without the abnormality, according to new data released at the Seventh European Breast Cancer Conference.
For women with human epidermal growth factor receptor type 2 (HER2)-positive early breast cancer, delaying trastuzumab until chemotherapy is completed may impair outcomes, according to findings from the landmark N9831 trial. The findings were presented by Edith Perez, MD, director of the Breast Cancer Program at the Mayo Clinic, Jacksonville, Florida.
Results 111 - 118 of 118